Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics

We compared symptom severity and quality of life (QOL) in schizophrenic patients adequately treated with typical antipsychotics (TAP) or clozapine (CZP). Groups did not differ in symptom severity or QOL. Clozapine caused fewer extrapyramidal symptoms. Negative and extrapyramidal symptoms predicted Q...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2005-02, Vol.133 (2), p.277-280
Main Authors: Strejilevich, Sergio A., Palatnik, Ana, Avila, Rubén, Bustin, Julián, Cassone, Julieta, Figueroa, Soledad, Gimenez, Mariana, de Erausquin, Gabriel A.
Format: Article
Language:English
Subjects:
Adult
Ambulatory Care
Antipsychotic Agents - adverse effects
Basal Ganglia Diseases - chemically induced
Basal Ganglia Diseases - epidemiology
Biological and medical sciences
Clozapine - adverse effects
Female
Humans
Male
Medical sciences
Negative symptoms
Neuropharmacology
Parkinsonism
Pharmacology. Drug treatments
Predictive Value of Tests
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Quality of Life
Schizophrenia - drug therapy
Treatment outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared symptom severity and quality of life (QOL) in schizophrenic patients adequately treated with typical antipsychotics (TAP) or clozapine (CZP). Groups did not differ in symptom severity or QOL. Clozapine caused fewer extrapyramidal symptoms. Negative and extrapyramidal symptoms predicted QOL. Similar outcome in both groups suggests a common ceiling to antipsychotic efficacy.
ISSN:0165-1781
1872-7123
DOI:10.1016/j.psychres.2004.10.009